Clinical
Conditions & ketamine research
Evidence, approval status and treatment risks differ by diagnosis and administration route. Explore the research and questions to discuss with a licensed physician in South Carolina.
Depression
Ketamine has been studied for treatment-resistant depression. A 2023 randomized trial compared IV ketamine with ECT in adults with nonpsychotic treatment-resistant major depression; its findings do not apply automatically to psychotic depression, every patient or every route. FDA-approved Spravato is esketamine, a different medication and administration program.
Read the guideAnxiety
Ketamine is not FDA-approved specifically for anxiety disorders. Evidence is smaller and more preliminary than the depression literature, and depression findings should not be presented as proof of anxiety treatment effectiveness. Established psychological and medication treatments remain part of a clinician-led assessment.
Read the guidePTSD
A small 2021 randomized controlled trial studied repeated IV ketamine in chronic PTSD. It is useful research, but does not establish long-term effectiveness for all patients or other administration routes. Ketamine treatment for PTSD is off-label; discuss established trauma-focused care and medication options with a qualified clinician.
Read the guideOCD
Ketamine is not FDA-approved specifically for OCD. Research is preliminary, and a response to ketamine in depression does not establish that it treats OCD. Ask a clinician about exposure and response prevention, medication and the evidence and risks for any off-label option.
Read the guideChronic Pain
Ketamine has been studied in selected chronic-pain conditions, but evidence, protocols and risk vary by diagnosis. Consensus guidance for IV ketamine in chronic pain does not support assuming that every pain condition benefits or that ongoing treatment is appropriate. Assessment by a licensed pain clinician is important.
Read the guideBefore you book
Approved, off-label, and why the difference matters
Ketamine is FDA-approved for anesthesia; psychiatric uses are off-label. Spravato is nasal esketamine with specific FDA-approved adult depressive indications, not a ketamine infusion. Neither approval nor one condition's study establishes effectiveness for other diagnoses or routes. Coverage and eligibility must be confirmed individually.
Ask about the evidence, potential harms, monitoring and established alternatives. A treatment provider should not promise outcomes or imply that off-label use is risk-free.
Ask any clinic these four questions
- 1. Is this medication and route approved for my diagnosis, or off-label?
- 2. Will you run the insurance authorisation, and what do you need from me?
- 3. Who supervises the sessions, and is a prescriber on site?
- 4. How will you assess response and decide whether to continue treatment?